Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
9.68
-0.24 (-2.47%)
Apr 16, 2024, 10:15 AM EDT - Market open
Theravance Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 40.38 | 299.01 | 90.8 | 82.3 | 58.9 | 378.85 | 89.81 | 345.54 | 113.54 | 90.05 | Upgrade
|
| Short-Term Investments | 62.88 | 29.31 | 83.51 | 211.47 | 222.77 | 127.26 | 259.59 | 156.39 | 59.73 | 165.4 | Upgrade
|
| Cash & Cash Equivalents | 103.26 | 328.32 | 174.3 | 293.77 | 281.66 | 506.11 | 349.4 | 501.93 | 173.27 | 255.44 | Upgrade
|
| Cash Growth | -68.55% | 88.36% | -40.67% | 4.30% | -44.35% | 44.85% | -30.39% | 189.69% | -32.17% | 30565.55% | Upgrade
|
| Receivables | 17.47 | 16.79 | 14.07 | 69.67 | 50.57 | 16.1 | 9.36 | 9.72 | 37.15 | 2.13 | Upgrade
|
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 16.83 | 12.22 | 10.01 | 12.55 | Upgrade
|
| Other Current Assets | 12.81 | 8.36 | 61.5 | 29.9 | 6.25 | 10.62 | 3.16 | 4.63 | 17.05 | 5.25 | Upgrade
|
| Total Current Assets | 133.54 | 353.46 | 249.87 | 393.34 | 338.49 | 532.82 | 378.75 | 528.5 | 237.47 | 275.37 | Upgrade
|
| Property, Plant & Equipment | 45.36 | 52 | 53.35 | 59.68 | 59.25 | 13.18 | 10.16 | 8.46 | 9.87 | 9.66 | Upgrade
|
| Long-Term Investments | 0 | 0 | 67.54 | 12.75 | 4.99 | 11.87 | 41.59 | 99.57 | 50.86 | 51.4 | Upgrade
|
| Other Long-Term Assets | 203.1 | 201.94 | 4.07 | 3.28 | 6.11 | 2.37 | 10.91 | 2.73 | 1.91 | 1.34 | Upgrade
|
| Total Long-Term Assets | 248.46 | 253.94 | 124.95 | 75.72 | 70.34 | 27.41 | 62.65 | 110.75 | 62.64 | 62.4 | Upgrade
|
| Total Assets | 382 | 607.4 | 374.82 | 469.06 | 408.83 | 560.24 | 441.4 | 639.25 | 300.12 | 337.77 | Upgrade
|
| Accounts Payable | 1.52 | 1.55 | 3.1 | 6.78 | 4.76 | 9.03 | 5.92 | 1.73 | 18.8 | 9.92 | Upgrade
|
| Deferred Revenue | 0 | 0.19 | 0.41 | 11.87 | 38.34 | 69.58 | 1.56 | 0.15 | 0.14 | 0.09 | Upgrade
|
| Current Debt | 3.92 | 6.75 | 17.44 | 29.2 | 17.61 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Current Liabilities | 19.32 | 20.22 | 37.64 | 75.72 | 51 | 19.95 | 55.07 | 47.38 | 30.52 | 31.25 | Upgrade
|
| Total Current Liabilities | 24.77 | 28.72 | 58.59 | 123.57 | 111.7 | 98.55 | 62.55 | 49.27 | 49.47 | 41.26 | Upgrade
|
| Long-Term Debt | 45.24 | 45.41 | 652.08 | 647.06 | 492.92 | 454.35 | 223.75 | 222.68 | 0 | 0 | Upgrade
|
| Other Long-Term Liabilities | 99 | 91.48 | 2.73 | 2.18 | 28.05 | 58.92 | 39.92 | 17.08 | 7.58 | 6.73 | Upgrade
|
| Total Long-Term Liabilities | 144.24 | 136.89 | 654.81 | 649.24 | 520.96 | 513.27 | 263.67 | 239.76 | 7.58 | 6.73 | Upgrade
|
| Total Liabilities | 169 | 165.6 | 713.39 | 772.81 | 632.67 | 611.82 | 326.22 | 289.02 | 57.05 | 47.98 | Upgrade
|
| Total Debt | 49.16 | 52.16 | 669.52 | 676.26 | 510.53 | 454.35 | 223.75 | 222.68 | 0 | 0 | Upgrade
|
| Debt Growth | -5.75% | -92.21% | -1.00% | 32.46% | 12.36% | 103.07% | 0.48% | - | - | - | Upgrade
|
| Retained Earnings | -909.1 | -853.91 | -1,726.04 | -1,526.62 | -1,248.6 | -1,012.15 | -797.74 | -512.23 | -321.56 | -139.34 | Upgrade
|
| Comprehensive Income | -0.07 | -0.02 | 0 | 0.05 | 0.15 | -0.17 | -0.73 | -0.25 | -0.07 | -0.08 | Upgrade
|
| Shareholders' Equity | 213 | 441.8 | -338.57 | -303.75 | -223.84 | -51.59 | 115.18 | 350.23 | 243.07 | 289.79 | Upgrade
|
| Net Cash / Debt | 54.1 | 276.16 | -495.22 | -382.48 | -228.86 | 51.76 | 125.65 | 279.25 | 173.27 | 255.44 | Upgrade
|
| Net Cash / Debt Growth | -80.41% | - | - | - | - | -58.81% | -55.00% | 61.17% | -32.17% | 30565.55% | Upgrade
|
| Net Cash Per Share | 0.98 | 3.75 | -7.13 | -6.13 | -4.12 | 0.96 | 2.40 | 6.25 | 5.07 | 8.04 | Upgrade
|
| Working Capital | 108.77 | 324.75 | 191.28 | 269.77 | 226.79 | 434.27 | 316.2 | 479.24 | 188 | 234.11 | Upgrade
|
| Book Value Per Share | 3.85 | 6.00 | -4.87 | -4.87 | -4.03 | -0.96 | 2.20 | 7.83 | 7.12 | 9.13 | Upgrade
|